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Abstract
Objective: To investigate neurodegenerative and inflammatory biomarkers in
people with amyotrophic lateral sclerosis (PALS), evaluate their predictive value
for ALS progression rates, and assess their utility as pharmacodynamic
biomarkers for monitoring treatment effects. Methods: De-identified, longitudi-
nal plasma, and cerebrospinal fluid (CSF) samples from PALS (n = 108; 85
with samples from ≥2 visits) and controls without neurological disease (n = 41)
were obtained from the Northeast ALS Consortium (NEALS) Biofluid Reposi-
tory. Seventeen of 108 PALS had familial ALS, of whom 10 had C9orf72 muta-
tions. Additional healthy control CSF samples (n = 35) were obtained from
multiple sources. We stratified PALS into fast- and slow-progression subgroups
using the ALS Functional Rating Scale-Revised change rate. We compared
cytokines/chemokines and neurofilament (NF) levels between PALS and con-
trols, among progression subgroups, and in those with C9orf72 mutations.
Results: We found significant elevations of cytokines, including MCP-1, IL-18,
and neurofilaments (NFs), indicators of neurodegeneration, in PALS versus
controls. Among PALS, these cytokines and NFs were significantly higher in
fast-progression and C9orf72 mutation subgroups versus slow progressors. Ana-
lyte levels were generally stable over time, a key feature for monitoring treat-
ment effects. We demonstrated that CSF/plasma neurofilament light chain
(NFL) levels may predict disease progression, and stratification by NFL levels
can enrich for more homogeneous patient groups. Interpretation: Longitudinal
stability of cytokines and NFs in PALS support their use for monitoring
responses to immunomodulatory and neuroprotective treatments. NFs also have
prognostic value for fast-progression patients and may be used to select similar
patient subsets in clinical trials.
Introduction
Amyotrophic lateral sclerosis (ALS) is an incurable
neurodegenerative illness. Motor neuron loss leads to
progressive weakness, with average survival 2–5 years
after diagnosis. ALS is heterogeneous for onset age,
site of onset, progression rate, cognition and behavior
changes, and survival duration.1,2 Most cases are
sporadic, whereas familial ALS exhibits an inheritance
pattern or a clear monogenic cause, such as mutations
in C9orf72 or other genes.3,4 Proposed pathogenic
mechanisms include excitotoxicity via glutamate recep-
tors, mitochondrial dysfunction, oxidative stress, pro-
tein aggregation, and neuroinflammation,2–6 but
symptom onset triggers and disease progression drivers
remain unknown.
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Only two drugs have U.S. Food and Drug Administra-
tion (FDA) approval for ALS. Riluzole is a glutamate-re-
lease inhibitor that improves survival ~3 months.7
Edaravone, a free radical scavenger that inhibits neuronal
death in animal models by reducing oxidative stress, ini-
tially failed in a broadly defined group of people with
ALS (PALS).8 A later trial showed a 33% slower decline
in the ALS Functional Rating Scale-Revised (ALSFRS-R)
over 6 months, specifically in edaravone-treated fast pro-
gressors versus placebo,9 leading to edaravone approval in
the United States in 2017. These studies highlighted the
importance of trial designs that enrich for PALS with
more homogeneous pathogenesis or disease progression
rates.
Given the modest effect of current therapies, finding
better treatments by improving trial design is vital.
Biomarkers may strengthen trial design by (1) allowing
selection of likely responders, (2) predicting disease pro-
gression, (3) reflecting target engagement, and (4) reflect-
ing treatment effects. Currently, there are no validated
biomarkers for ALS drug development.10 Promising can-
didates include neurofilaments (NFs), essential structural
components of neuronal axons. Mutations in phosphory-
lated neurofilament heavy chain (pNFH) are linked to
ALS,11 and elevated NFs in cerebrospinal fluid (CSF) and
blood indicate motor neuron dysfunction and axonal
injury in ALS and other neurodegenerative diseases.1,11–16
Early evidence suggests that neurofilament levels rise in
the year prior to symptom onset in presymptomatic peo-
ple carrying a mutation in the SOD1 gene.17 In symp-
tomatic PALS, both neurofilament light chain (NFL) and
phosphorylated neurofilament heavy chain (pNFH) levels
have been shown to be elevated in people with ALS and
have been correlated with patient survival; prompting
investigations into their use for stratifying PALS into
prognostic subsets.14,18–21 While NFL and pNFH have
been reported to be essentially stable over time,14,17 some
uncertainty remains. Better characterization of this longi-
tudinal stability will help set the stage for the use of neu-
rofilaments as markers of treatment response in early
phase ALS trials.
Both nonclinical studies of transgenic rodents and clin-
ical studies of patients with familial ALS implicate neu-
roinflammation and immune dysregulation in
pathogenesis and heterogeneity.6,22 Activated astrocytes,
microglia, and MCP1-CCR2–mediated infiltration of
monocytes have been detected in the motor cortex of
ALS patients and TDP-43 mouse models.23 Lu et al.
demonstrated higher levels of creatine kinase, ferritin,
TNF-a, and interleukins in plasma samples from PALS
compared to controls, indicating that systemic inflamma-
tory biomarkers acting on T-cell responses affected neuro-
muscular ALS pathology.24 In addition, C-reactive protein
(CRP), a general biomarker of inflammation, has been
shown to be elevated in the serum of PALS and to corre-
late with more rapid disease progression.25 Mutations in
triggering receptor expressed on myeloid cells 2 (TREM2),
a receptor of the innate immune system expressed on
microglia, macrophages, dendritic cells, and osteoclasts,
are associated with ALS, Alzheimer’s Disease (AD), and
frontotemporal dementia (FTD).26 Soluble TREM2
(sTREM2), a proteolytic product of TREM2, may indicate
activated myeloid cells in both the central nervous system
(CNS) and the periphery.27
Despite mounting evidence supporting the role of neu-
roinflammation in ALS, results from immunosuppressive
approaches have been discouraging; they have not slowed
disease progression, which suggests nuanced immune dys-
regulation.28 This failure of immune suppression may be
attributable to the complexity of the inflammatory
response in ALS. Future efforts should aim for careful
immunomodulation, rather than broad immunosuppres-
sion, a goal more readily achieved if guided by a clear
understanding of the specific inflammatory responses
within individual ALS patients.
To better characterize biomarkers of neurodegeneration
and inflammation in ALS, we obtained longitudinal
plasma and CSF samples that had been collected prospec-
tively from PALS and controls and stored in the North-
east ALS (NEALS) Consortium biorepository. We first
modeled individuals’ disease progression, identifying fast-
and slow-progressing subgroups. We then examined
inflammatory cytokine and NF levels in CSF and plasma,
comparing PALS progression among subgroups and to
controls without neurological disease. Then, we assessed
the stability of these candidates over time. Finally, we
evaluated the use of NF levels for patient selection and
sample size calculations for clinical trials.
Methods
Sources of CSF and plasma samples
De-identified plasma and CSF samples from PALS
(n = 108) and controls without neurological disease
(n = 41) were obtained from the NEALS Biofluid Reposi-
tory. Eighty-five of the 108 PALS had samples available
from two or more visits. Longitudinal CSF and blood
samples and accompanying clinical information were col-
lected between 2011 and 2016 in a prospective, centrally
coordinated, multicenter study to establish a source for
longitudinal biomarker studies (ClinicalTrials.gov:
NCT01495390). Briefly, participants were enrolled at six
centers; detailed clinical information and biofluid samples
(CSF, serum, and plasma) were obtained at baseline and
at follow-up visits, approximately every 4 months for up
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to 2 years. Samples were collected with standardized pro-
tocols and processed immediately. Briefly, CSF was cen-
trifuged, aliquoted into cryovials, and frozen at 80°C.
Blood was collected using K2EDTA tubes and centrifuged
at 1750 g for 10 min. Supernatants were aliquoted into
cryovials and frozen at 70°C to 80°C. Repeat-primed
PCR testing for C9 hexanucleotide repeat expansion
mutations was conducted on all samples at the Cecil B.
Day Laboratory for Neuromuscular Research (University
of Massachusetts Medical School, Worcester, MA). All
visits included characterization of a battery of clinical
outcomes including: the Fronto-Temporal Dementia
(FTD) Assessment to assess any subtle cognition and
behavior dysfunction; the ALSFRS-R to measure bulbar,
motor, and respiratory functions; and slow vital capacity
(SVC) to measure pulmonary function. Raters for these
measures were trained by the NEALS Outcomes Training
Center at the Barrow Neurological Institute.
In addition to the non-neurological controls from
NEALS, we included CSF samples from aged, healthy
controls obtained from multiple sources, and included
baseline samples from Denali-sponsored clinical studies
(n = 15) or that were purchased commercially from Inno-
vative Research (Novi, MI, USA; n = 17) and Sanguine
Biosciences (Sherman Oaks, CA, USA; n = 3). These sam-
ples were collected using protocols similar to those used
for the PALS cohort and were centrifuged, aliquoted, and
stored at 80°C.
Written informed consent was obtained from all study
participants who contributed information or samples.
Multiplex cytokine immunoassay
We measured levels of a large panel of cytokines in CSF
(see Table S1 for a list) using the Luminex multiplex
immunoassay platform at Eve Technologies (Calgary,
Canada) with the Bio-PlexTM 200 system (Bio-Rad Labora-
tories, Inc., Hercules, CA, USA) and a Milliplex Human
Cytokine kit (Millipore, St. Charles, MO, USA) according
to manufacturer protocols. The reported lower limit of
detection (LLOD) for the 65 markers ranged from 0.1–
55.8 pg/mL (intra-assay coefficient of variation [CV]:
2.58%  1.06%; interassay CV: 10.73%  4.02% [mean,
SD]). Eve Technologies provided assay quality control
(QC) data. Each Luminex sample was measured by two
technical replicates. To ensure consistency, samples were
excluded for analytes with more than 50% of measure-
ments outside the range of quantification, a technical
replicate CV greater than 80%, or with one technical
replicate missing. Although this method may bias against
cytokines that have low values for which variation is likely
higher, we aimed to prioritize cytokines that could be
robustly detected with current assay. Sample results were
summarized as the arithmetic mean of the two technical
replicates.
Meso Scale Discovery (MSD) cytokine assays
For clinical biomarker development, singleplex
immunoassays have the advantage of ensuring the optimal
detection of each target in different matrices with optimal
dilutions and minimal interference from other antibody
pairs,29 in addition to integration with automation sys-
tems for operational precision. We thus selected a panel
of various cytokines of interest including MCP-1,
eotaxin-1, IL-18, TNF-a, CRP, and IL-15 and measured
them in plasma using a well-characterized MSD V-Plex
assay system (Meso Scale Discovery, Rockville, MD, USA)
following manufacturer instructions. MCP-1, IL-15 and
CRP in CSF were also measured using MSD V-Plex with
optimal dilution factors that were determined at Denali
Therapeutics to confirm the Luminex data.
Soluble triggering receptor expressed on
myeloid cells 2 (sTREM2) assay
sTREM2 levels in CSF and plasma were measured with an
MSD plate-based immunoassay developed at Denali Ther-
apeutics using a biotinylated goat anti-human TREM2
antibody (BAF1828; R&D Systems, Minneapolis, MN,
USA) and a sulfo-conjugated rat anti-human TREM2
antibody (MAB 17291; R&D Systems, Minneapolis, MN,
USA) for capture and detection, respectively. sTREM2
CSF and plasma concentrations were determined by inter-
polating from a standard curve generated using recombi-
nant human sTREM2.
Neurofilament light chain (NFL)
NFL measurements in CSF and plasma were performed at
Quanterix (Billerica, MA, USA). The Simoa NF-LIGHT
assay used an optimized dilution factor for each matrix.
Technical replicates were run for all samples, and all val-
ues were within the assay’s linear range. Concentrations
were interpolated from the standard curve and adjusted
by dilution factors.
Phosphorylated neurofilament heavy chain
(pNFH)
pNFH was measured in a subset of all CSF samples with
an MSD immunoassay employing a mouse anti-human
pNFH antibody and a sulfo-tagged polyclonal anti-pNFH
antibody for capture and detection, respectively. The assay
was analytically validated as a laboratory-developed test at
Iron Horse Diagnostics, Inc. (Scottsdale, AZ, USA), in a
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 3
F. Huang et al. Longitudinal Biomarkers in ALS
Clinical Laboratory Improvement Amendments (CLIA)-
certified laboratory. Samples were tested in duplicate, with
a CV below 8%. Intra- and interassay CVs were <10%.
Statistical analysis
Categorization of fast/slow progressors using
modeled progression rates
Of 108 ALS patients, we used data from 85 patients with
at least two ALSFRS-R measurements to model progres-
sion rates. A multivariate linear mixed-effects model of
ALSFRS-R, adjusting for age at disease onset, disease
duration at the time of reported visit, sex, ALS family his-
tory, and all pairwise interactions with disease duration,
along with a subject-specific random intercept and slope,
were fit to the data.
A linear mixed-effects model of ALSFRS-R was used to
model progression of patients who had at least two
observed time points. Specifically,
Yijk ¼ a0 þ a1X1i þ a2X2ij þ a3X3i þ a4X4i þ a5X1iX2ij
þ a6X3iX2ij þ a7X4iX2ij þ b0i þ b1iX2ij þ ijk
where Yijk is the modeled ALSFRS-R score for patient i at
time j at some repeated measure k, X1i is the age of onset
of disease for patient i, X2ii is the recorded disease dura-
tion in years for patient i at time j, X3i is the categorical
variable representing the gender of patient i, X4i is the
categorical variable representing whether patient i had a
family history of ALS, a0–a7 are estimated model coeffi-
cients, b0i and b1i are patient-specific random effects, and
eijk is the resulting error associated with model residual
error modeled as a Gaussian distribution with variance
r2 . Furthermore, we model a correlation structure
between the patient specific random effects b0i and b1i. To












ijk N 0; rð Þ
where N 0; rð Þ represents normally distributed with
model-estimated mean and variance/covariance matrix.
The fitted model was used to estimate the predicted
rate of progression as defined by YiL  YiM where times L
and M are separated by 1 year. To confirm the validity of
the model in predicting rates of progression, empirically
observed progression rates were estimated for each patient
as well. To calculate observed progression rates, a linear
decline was assumed from age of onset when the
ALSFRS-R score was assumed to be the maximum of 48
points to the last observed ALSFRS-R score. This can be
expressed as
observed progression rate for patient i
¼ Y 0iLast  48
 
X2iLastð Þ
where Y 0iLast is the last observed ALSFRS-R score and
X2iLast is the recorded disease duration at this last
observed ASLFRS-R score.
A summary figure (Fig. 1A) comparing observed and
modeled progression rates shows that the model accu-
rately predicts progression rates while helping to smooth
some of the extreme progression rates that would be
empirically observed. To ensure sufficient distinction
between fast and slow progressors for comparing sub-
groups, we proposed leaving a gap and excluding subjects
with modeled ALSFRS-R declines between 4 and 9.6
points per year. This separation is arbitrarily chosen but
helps to clearly distinguish differences in biomarker levels
between the two extremes of the ALS population in terms
of progression.
The fitted model was used to predict each patient’s
progression, and PALS were stratified by the model-esti-
mated rate of disease progression. Patients with a model-
estimated drop in the ALSFRS-R of greater than 9.6/year
(0.8/month) or less than 4.0/year (0.33/month) were cate-
gorized as slow (Fig. 1B) or fast (Fig. 1C) progressors,
respectively. Visual inspection showed that fast progres-
sors were uniformly captured in this model. Patients with
C9orf72 fell mainly into the fast-progression group
(Fig. 1D). The goal of modeling progression was to bor-
row population information to robustly categorize
observed patients as fast or slow progressors. As such, the
specified model was designed as an ALSFRS-R prediction
model for this specific population and was not intended
as an inferential model for the covariates.
Observed progression rates
Observed progression rates were computed as a linear
decline for each subject from the last observed time point
based on length of disease, assuming an ALSFRS-R score
of 48 at disease onset. This empirical estimate is more
prone to extreme observations than the modeled progres-
sion discussed above but is useful as a validity check to
the modeled progression rates and for discussions relating
to the selection (inclusion/exclusion) of a trial population
where all individuals must be categorized.
Modeling differential effects
All measured analyte concentrations were log transformed
and modeled using a linear mixed-effects model on
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progression subgroups with a subject-specific random
intercept to account for the intrasubject correlation struc-
ture of multiple measurements over time. All models were
adjusted for age and sex. Where appropriate, a Ben-
jamini–Hochberg procedure was used to adjust for com-
parison across multiple hypotheses.
Modeling longitudinal stability of NFs and
cytokines
Average longitudinal trends in NFL, pNFH, and selected
cytokines were modeled as a constant rate of change over
time. To account for potential differences across individu-
als, a linear mixed-effects model of the independent vari-
able, analyte log concentration, was modeled on the
disease duration with a subject-specific random intercept
and slope. An unstructured covariance matrix was
assumed between the subject-specific random intercept
and slope parameters.
Correlation analysis
To estimate correlations, Pearson’s correlation was com-
puted between associated analytes.
Survival analysis
Subjects were divided into equal groups of “high” and
“low” by baseline analyte concentrations, separated by the
median among all measured PALS. We then fit a Cox
proportional hazards model to the data, adjusting for site
of onset, gender, and age of disease onset. We performed
a statistical test of significance based on Wald’s method.
Estimating impact of neurofilaments on clinical
trial design
We briefly explored two potential uses for NFs in ALS
clinical trials. First, we examined the potential benefit of
using NF levels for trial selection. Because slow progres-
sors contribute less information, including large percent-
ages of slow progressors in clinical trials can reduce
statistical power. We therefore evaluated the effect of
using an NF threshold for trial inclusion to reduce the







































































Figure 1. (A) Comparison of observed versus modeled progression
rates. ALSFRS-R trajectories over the course of disease for (B) slow-
progression, (C) fast-progression, and (D) C9orf72 subgroups. Slow
and fast progressors were defined as those patients showing a drop
in the ALSFRS-R of less than 0.33/month or greater than 0.8/month,
respectively
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on our plasma NFL analyses and examined the impact of
using this threshold on patient selection. Second, we per-
formed exploratory sample size calculations for clinical
trials based on the CV of NFL in CSF and in plasma. For
these calculations, we assumed a power of 80% at an
alpha level of 0.2. We chose an alpha level of 0.2 because
for this use-case, NF would support early phase proof-of-
concept studies.
Statistical software
All data processing and analysis was done using R soft-
ware, version 3.6.1 (https://rstudio.com/products/rstudio/
download/). Modeling of mixed effects models was done
using the lme4 package, whereas figures were generated
using the ggplot2 package.
Results
Demographics
Demographic characteristics of the PALS and non-ALS
control groups were similar, except that more PALS were
Caucasian, and PALS were older (PALS, mean [SD] age
at diagnosis 56.9 [10.0] years); Table 1). Twenty PALS
were fast progressors and 34 were slow progressors, as
defined by our model. Seventeen of 108 PALS had famil-
ial ALS, of whom 10 had C9orf72 mutations; nine of
those 10 were rapid progressors.
Cytokine analyses
Of 65 cytokines measured using multiplex panels, PALS
had significant increases of cytokine/chemokines including
MCP-1 (128.8% of controls, adjusted P < 0.01], IL-18
(148.7% of controls, adjusted P < 0.01), and MIP-1a
(120.5% of controls, adjusted P = 0.01) and significant
decreases of 6CKine (adjusted P = 0.03), CTACK (ad-
justed P < 0.01) and PDGF-AA (adjusted P < 0.01) com-
pared with non-ALS controls (Fig. 2A; Table S1). Based
on the CSF cytokine data, we used MSD assays to mea-
sure a selected group of cytokines in plasma, and found
plasma MCP-1 (125.7% of controls, adjusted P = 0.02)
and IL-18 (124.8% of controls, adjusted P = 0.02) levels
in PALS were also significantly increased (Fig. 2B). How-
ever, the association between central (CSF) and peripheral
(plasma) levels of these cytokines was minimal (MCP-1,
Pearson r: 0.06 [0.05, 0.18]; IL-18, Pearson r: 0.29 [0.19,
0.39]). We also examined the effect of age on cytokine
levels, appropriately adjusting for modeling differential
effects. We found that IL-15 and Flt-3L in CSF were posi-
tively correlated with age (IL-15, Pearson r: 0.61, 95% CI
[0.49, 0.7]; Flt-3L, Pearson r: 0.59, 95% CI [0.48, 0.69]).
MCP-1 and IL-18 were more elevated in CSF from the
C9orf72 and fast-progression groups compared to slow-
progression and control groups (Table 2; Fig. 3); plasma
levels did not differ between subgroups (Table 2; Fig. 3).
While CSF 1L-15 was not elevated in the PALS group





Sex, male, no. (%) 52 (65.8) 60 (55.6)
Ethnicity, no. (%)
Asian 3 (3.8) 1 (0.9)
Black 2 (2.5) 3 (2.8)
Caucasian 53 (67.1) 100 (92.6)
Hawaiian 0 1 (0.9)
Hispanic/Latino 3 (3.8) 2 (1.9)
Multiracial 1 (1.3) 1 (0.9)
Unknown 6 (7.6) 0
NA 11 (13.9) 0
Age, mean (SD), years 43.4 (11.8) 56.9 (10.0)
Site onset, no. (%)
Bulbar 0 22 (20.4)
Limb 0 86 (79.6)
NA 79 (100.0) 0
Genetics, no. (%)
C9orf72 0 10 (9.3)
Others 0 7 (6.5)
ALSFRS-R, 1st visit, mean (SD)1 NA 36.7 (6.9)




DNLI-A-0001 baseline2 3 (3.8) 0
DNLI-B-0001 baseline2 12 (15.2) 0
Innovative research2 17 (21.5) 0
NEALS 41 (51.9) 108
(100.0)
Sanguine2 6 (7.6) 0
Disease progression subgroups3
Fast (ALSFRS-R change >9.6/
year)
NA 20








Subjects with only one visit NA 23
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-
Revised; NA, not applicable; predmax, predicted maximum; SVC, slow
vital capacity.
1ALSFRS-R scores and SVC values were determined during the first
patient visit.
2Only CSF samples.
3Disease progression subgroups were defined according to the model-
estimated rate of disease progression described in the Methods.
4C9orf72 subjects overlap with the other progression subgroups; nine
were fast progressors.
6 ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
Longitudinal Biomarkers in ALS F. Huang et al.
overall, it was elevated in the fast-progression and C9orf72
groups (Fig. 3A). In plasma, however, IL-15 showed the
opposite trend when comparing subgroups (Fig. 3B), indi-
cating potentially different mechanisms for central and
peripheral regulation of this cytokine. CRP was not
increased in PALS, but there was a trend toward elevated
CRP in CSF and plasma in C9orf72 patients (Table 2).
Interestingly, tumor necrosis factor a (TNF-a) was signifi-
cantly increased in CSF and plasma from C9orf72 patients
(Table 2; Figure S1A, B), consistent with data indicating a
potential role for autoimmunity particularly in C9orf72
ALS individuals. Other inflammatory cytokines (IL-6, IL-
23, and IL-17) were not significantly different from controls
in CSF (IL-6, Table 2; data not shown).
In the PALS group, sTREM2 levels were elevated in
plasma (Fig. 2B), but not in CSF (data not shown), com-
pared with controls. However, sTREM2 was significantly
increased in both CSF and plasma of the fast-progression
and C9orf72 groups (Table 2; Fig. 3), suggesting activa-
tion of both central microglial cells and peripheral macro-
phages. In CSF, sTREM2 showed high correlation with
IL-15 (Pearson r = 0.68), modest correlation with IL-18
(Pearson r = 0.38), and MIP-1a (Pearson r = 0.44), but






























































Figure 2. Inflammatory cytokines and glial cell markers in (A) CSF and (B) plasma with significant differences between PALS and non-ALS
controls. Each dot represents an individual patient visit and box plots indicate median  interquartile range (IQR).
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In longitudinal samples from PALS (n = 85; follow-up
duration range: 4 months to 2 years), MCP-1 and IL-18
levels in CSF showed an estimated rate of annual change
in 1.4% for MCP-1 [95% CI: 0.8%, 3.6%] and 3.4%
for IL-18 [95% CI: 6.7%, 0.0%]), and in plasma of
1.1% for MCP-1 [95% CI: 1.7%, 4.0%] and 3.4% for
IL-18 [95% CI: 7.2%, 0.6%] (Fig. 4A, B). sTREM2
levels were similarly stable (Figure S1C).
Neurofilaments
NFL was elevated in PALS in both CSF (712.2% of con-
trols, P < 0.01) and plasma (412.7% of controls,
P < 0.01) (Fig. 5A, B). NFL levels in plasma and CSF cor-
related highly (Pearson r = 0.69, Fig. 5C). pNFH was ele-
vated in PALS in CSF (485.1% of controls, P < 0.01).
NFL and pNFH levels correlated highly in CSF (Pearson
r = 0.85, Fig. 5D), but showed only modest correlation in
plasma (Pearson r = 0.47, data not shown).
When stratifying PALS by disease progression rate,
NFL in CSF and plasma and pNFH in CSF were signifi-
cantly higher in fast-progression and C9orf72 mutant
groups compared to the slow-progression group and con-
trols (Table 2; Fig. 5E–G). We performed additional anal-
yses to examine the impact of NFL (in CSF), along with
the cytokines MCP-1 (in CSF) and sTREM2 (in CSF), on
predicting survival. When subjects were stratified into
“high” and “low” groups by the median baseline concen-
tration of each analyte, we found that NFL was a
significant prognostic factor for survival, but MCP-1 and
sTREM2 were not (Figure S2).
In samples from our study population, levels of NFL
were stable over time, with an estimated rate of annual
change in only 3% in CSF [95% CI: 3.3%, 9.8%]), and
3.8% in plasma [95% CI: 8.4%, 1.1%]). Levels of
pNFH also remained stable with an estimated rate of
annual change in 0.8% in CSF [95% CI: 5.3%, 7.4%]
(Fig. 4C, D).
Based on our analysis of neurofilaments, we chose a
cutoff of 40 pg/mL for plasma NFL as a threshold for
inclusion into a hypothetical ALS trial based on the cur-
rent assay. This plasma NFL threshold considerably
reduced the percentage of slow progressors from 41% to
13% (Fig. 5H). Our exploratory sample size calculations
for clinical trials based on an NFL CV in CSF and plasma
demonstrated that, with 10 participants per arm, we
would be able to detect NFL changes in 35% in CSF and
44% in plasma to reach nominal statistical significance
(P < 0.2) with 80% power (Table 3). Increasing the sam-
ple size to 30 patients per arm allows the statistically sig-
nificant detection of 21% and 27% changes in NFL in
CSF and plasma, respectively.
Discussion
Drug development for ALS has been hindered by the lack
of understanding of ALS pathogenesis and effective
biomarkers. It is clear that neuroinflammatory responses
















MCP-1 128.8% 121% 139% 177% <0.01 <0.01 <0.01
IL-18 148.7% 135% 201% 174% <0.01 <0.01 <0.01
MIP-1a 120.5% 111% 137% 135% 0.01 <0.01 <0.01
CRP 138.9% 112% 137% 266% 0.56 0.08 0.50
IL-15 101.9% 95% 111% 122% 0.75 0.09 0.28
TNFa 111.1% 102.4% 120.6% 135.5% 0.15 <0.01 0.01
IL-6 97.5% 90.5% 92.9% 92.6% 0.70 0.65 0.60
sTREM2 93.5% 83% 128% 136% 0.56 0.04 0.05
NFL 712.2 320.3% 1414.6% 1642.5% <0.01 <0.01 <0.01
pNFH 485.1% 251.3% 799.5% 1155.2% <0.01 <0.01 <0.01
Plasma analyte
MCP-1 125.7% 141.7% 130.9% 136.6% 0.02 0.04 0.03
IL-18 124.8% 129.4% 127.% 142.7% 0.02 0.02 0.05
NFL 412.7% 247.7% 683.6% 977.6% <0.01 <0.01 <0.01
IL-15 94.6% 95.2% 92.5% 83.7% 0.44 0.04 0.28
TNF-a 103.5% 93.4% 91.2% 229.5% 0.81 <0.01 0.65
sTREM2 123.6% 116.5% 134.2% 146.8% 0.02 0.01 0.02
CRP 116.2% 87.6% 89.5% 181.1% 0.76 0.02 0.77
Estimates and P-values are based on a linear mixed-effects model that accounts for repeated longitudinal measures structure within subject. Note
that P-values are reported as adjusted P-values.
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are present and that there may be important biomarkers
reflecting these changes, but rarely have markers of
inflammation been explored in large longitudinal cohorts.
NFs appear to be reliable, though nonspecific, markers of
ALS. They may be useful in predicting rate of progres-
sion, stratifying participants, and/or demonstrating a
treatment effect. While a great deal of elegant work has
been done to evaluate NFs in ALS, and some work has
explored markers of neuroinflammation in plasma and
CSF from people with ALS, our study bolsters and
extends the existing evidence using cutting-edge tech-
niques to quantify and correlate a large set of biomarkers
in a large, longitudinally collected set of plasma and CSF
samples from carefully characterized people with ALS.
Extending the findings of previous reports that found
activated central and peripheral immune cells in
ALS,6,15,27,30 we found significant elevations of the proin-
flammatory cytokines MCP-1, MIP-1a, and IL-18 in CSF
of PALS compared with non-ALS controls. Specifically,
elevated MCP-1 (CCL2) and MIP-1a (CCL3), both CC
chemokines, implicate macrophage and microglia chemo-
taxis, leading to microgliosis activation in the CNS.28,30-32
Increased IL-18 in both CSF and plasma support inflam-
masome-mediated mechanisms.27,30 Elevated plasma
MCP-1 and IL-18 in PALS also suggests peripheral
immune activation, but we saw no significant correlation
between central and peripheral levels, indicating differen-
tial cytokine regulation in these compartments.
The biology determining the heterogeneity in the rapid-
ity of ALS progression is poorly understood. Our study
begins to address this knowledge gap by demonstrating
important differences in inflammatory cytokines between
PALS with slow and fast disease progression. Both fast-
progression and C9orf72 PALS exhibited robust increases
of MCP-1, IL-18, IL-15, and the microglial cell marker,
sTREM2, in CSF. In general, PALS with C9orf72 muta-
tions tend not to be slow progressors.13 Indeed, in our












































































Figure 3. Cytokine levels in (A) CSF and (B) plasma in disease progression subgroups. Box plots indicate median  IQR.
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progressors, so it remains unclear if the elevated cytokines
in this group are due to the effects of the specific geno-
type or simply reflect the faster disease progression.
Recent research in C9orf72 ALS individuals and preclini-
cal animal models with human C9orf72 mutations
increasingly suggests a potential role for autoimmu-
nity.33,34 Indeed, TNF-a seems to be specifically higher in
the C9orf72 group in both CSF and plasma. Elevations in
inflammatory cytokines and sTREM2, markers of acti-
vated microglial cells and macrophages in fast progressors
and C9orf72 ALS patients, suggests activation of glial cells
and peripheral immune cells at variable magnitudes
depending on the disease progression rate. Our data sub-
stantiate previous studies showing activation of microglia
and astrocytes, the appearance of lymphocytes and infil-
trating monocytes in postmortem tissue of PALS and in
the spinal cord of transgenic mice expressing a mutant
form of human SOD1,32,35 and the systemic regulation of
inflammatory biomarkers mostly active on T-cell immune
responses.24 While plasma MCP-1, IL-18, and sTREM2
are higher in the fast-progression groups, IL-15 in plasma
shows the opposite trend, likely reflecting the complexity
of adaptive immune system regulation depending on dis-
ease stage.6,32,36
This report is the first to analyze a comprehensive
panel of cytokines in longitudinal PALS CSF samples. We
demonstrate the general stability of MCP-1 and IL-18
levels in both CSF and plasma over the course of disease.
Differences in cytokine levels between patient subgroups
and their longitudinal stability suggest that these markers
could be used to select subsets of PALS for a clinical trial
or to evaluate treatment response.
Our observations of robust increases in NFL in CSF
and plasma and pNFH levels in CSF from PALS supports
prior evidence for their suitability as disease biomark-
ers.11,15 Importantly, central and peripheral NFL levels
were well correlated, which would allow for sample col-
lection using plasma instead of CSF, improving the feasi-
bility of implementation and reducing patient burden and
cost. pNFH levels in CSF and plasma were correlated,
although not as strongly as CSF and plasma levels of
NFL. While pNFH and NFL were correlated strongly in
CSF, their correlation in plasma was less robust. This
finding could be because of assay variability, biological
variability, or they may contain slightly nonoverlapping
information about the biology of ALS. For trialists select-
ing an assay, either pNFH or NFL from CSF could be
evaluated, but NFL appears to have an advantage over
pNFH when measured in the plasma.
Consistent with previous reports,18,37 we confirmed
that NFL in CSF and plasma and pNFH in CSF were sig-
nificantly elevated in PALS and essentially stable when
sampled repeatedly over time. We also confirmed signifi-
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Figure 4. Longitudinal analysis of (A) MCP-1, (B) IL-18, (C) NFL, and (D) pNFH in CSF and plasma of PALS (n = 85). Solid lines are the average
trajectory of log MCP-1, IL-18, NFL, and pNFH levels from the multilevel model analysis, and dotted lines represent the analyte trajectories of
individual PALS. For better visualization, only subjects in the first 8 years of disease are included. Values within each plot indicate the estimated
rates of annual change with 95% confidence intervals (CIs).
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patients, consistent with prior reports of NF level correla-
tions with disease progression and patient survival.11,14 In
addition, we confirmed previous studies that NFL was a
significant prognostic factor for survival.11,14 Cytokines
did not have a similarly robust prognostic value for sur-
vival, but these findings might be attributed to the small
magnitude of changes, intersubject variations, and poten-
tial comorbidity factors in cytokine regulation. C9orf72
patients also had higher levels of NFs, which appears to
simply reflect their faster disease progression in our
cohort, although it is challenging to discern whether the
mutation itself impacts NF levels, because all but one of
our participants with C9orf72 mutations were fast pro-
gressors.
NFs could be used as prognostic biomarkers to enrich
a trial population and improve ALS clinical trial effi-





















































































































































































Figure 5. NF levels in CSF and plasma in PALS, PALS subgroups, and non-ALS controls. NFLs in PALS and non-ALS controls in (A) CSF and (B)
plasma. (C) Correlation of CSF and plasma NFL levels. (D) Correlation of CSF NFL and pNFH levels. Values within the plot indicate the Pearson r
and 95% CI. NFL levels in (E) CSF and (F) plasma, and (G) pNFH in CSF in the non-ALS cohort, the slow- and fast-progression PALS, and the
C9orf72 group. (H) Observed progression rates versus plasma NFL levels, modeled using an ALSFRS-R score of 48 at disease onset and an NFL
cutoff of 40 pg/mL in 105 PALS. Nonslow progressors were defined by an observed decline of ≥4 points/year in the ALSFRS-R score. “Others”
include PALS with an ALSFRS-R change in 4–9.6/year and those with single timepoint sampling. Box plots indicate median  IQR.
Table 3. Sample size calculation for a phase 2a study design using
plasma and CSF NFL as primary biomarker endpoints.
Sample Size MDB in CSF (%) MDB in plasma (%)
N = 10 35 44
N = 15 29 37
N = 20 25 32
N = 25 23 29
N = 30 21 27
Table provides MDB of treatment versus placebo under various
sample size options (N per arm). Assumptions: analyte: NFL CSF
ESDDL-2 = 0.56, 15% dropout, alpha = 0.2; analyte: NFL plasma
ESDDL-2 = 0.76, 15% dropout, alpha = 0.2. ESDDL-2 = estimated
standard deviation of the delta difference between 2 log base 2
measurements. MDB = minimally detectable benefit: the smallest
percent reduction needed to reach statistical significance (P < 0.2)
with 80% power.
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illustrates a sample size benefit to using NFs as selection
criteria. Still, further NF assay characterization and valida-
tion with an independent cohort of patients are required
to establish applicable cutoffs for trials. Unfortunately we
did not have pNFH data on all longitudinal plasma sam-
ples and could not perform a similar analysis for pNFH,
nor could we perform a correlation analysis between the
two NF proteins in longitudinal plasma samples.
In addition, our model of longitudinal data showed rela-
tively stable NF levels during the course of disease, high-
lighting their potential use as pharmacodynamic markers
in short-term, proof-of-concept phase 2 ALS studies. Pre-
clinical studies are encouraging, showing that NF levels
respond to disease-modifying therapies in multiple sclerosis
and ALS models.38,39 Furthermore, clinical studies in multi-
ple sclerosis have also shown that NF levels respond to
treatment,38,40 and in infants with spinal muscular atrophy
(SMA), nusinersen treatment reduced plasma pNFH levels
(ENDEAR trial).41 Additionally, treatment-dependent NFL
changes have been observed in a small phase I trial of peo-
ple with SOD1-mediated ALS treated with antisense
oligonucleotides.42 The reliability and stability of NFL and
pNFH (CSF) in our study bolsters the proposal that NF
levels can act as useful tools for ALS trial design. While the
degree of expected and clinically meaningful NF changes in
response to different therapies is still unknown, this study
provides a starting point for determining the sample sizes
and power required to detect NF changes in different mag-
nitudes, although the actual utility of NFs as pharmacody-
namic biomarkers will only be verified once we have truly
effective treatments for ALS.
Because ALS progresses rapidly, limitations of our
study include potential biomarker sampling biases. Col-
lecting multiple measurements in the fast-progression
group was more challenging, so higher numbers of slow
progressors were included in the study cohort. In addi-
tion, the fast-progression group defined here may not
reflect patient groups enrolled in clinical studies. For
example, PALS in the edaravone phase 3 trial showed an
average ALSFRS-R change in >1.2/month,8 which is faster
than our definition. Our population also excluded
patients who only had samples from a single visit from
our disease progression analysis, and some may have been
fast progressors. Indeed, we observed high baseline cyto-
kine and NF levels in subjects with sampling from a single
timepoint and disease onset of less than 3 years. Another
limitation is that the controls were not all healthy subjects
and were not perfectly age- and race-matched to the
PALS population. However, we ensured that control sam-
ples were collected with the same protocols used to collect
PALS samples and were corrected for age, gender, race,
and sample resources during the data analysis. We also
acknowledge that comorbidities may have been
confounding factors in our analysis, but we did not
include them in the model given the challenges in data
interpretation that would have arisen with the small sam-
ple sizes for each comorbidity category. Future analysis
with a large dataset is warranted to investigate this aspect.
In summary, our data support a role for inflammatory
mechanisms in ALS pathogenesis, especially in patients
with fast disease progression. Furthermore, our data sup-
port the rationale for patient stratification depending on
the mechanism of action of the therapy (inflammation or
neuroprotection) and enrichment of a more homoge-
neous population. Specifically, the inflammatory markers
MCP-1, MIP-1a, and IL-18 in CSF and MCP-1 and IL-18
in plasma appear to be markers of inflammation. NFs are
reliably elevated in ALS, stable over time, and predictive
of the rate of progression and survival. Ultimately, these
data may improve the design of future clinical trials and
increase the probability of identifying more effective treat-
ments for ALS.
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Figure S2. Summary of survival analyses in PALS with
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